In the past few years, anti‐IDH1 or IDH2 targeted therapies have been actively evaluated alone or in association with 5‐azacytidine in refractory, relapsed or newly diagnosed AML [18, 19, 20]. This evidence concerns the gene IDH2 and acute myeloid leukemia.